Clinical Trials Browser

OTHER × Squamous Cell Carcinoma of Head and Neck × Tiragolumab × Clear all

NCT05681039 2026-06-02

Phase 2 Trial of Neoadjuvant and Adjuvant Tiragolumab Plus Atezolizumab in Patients With Newly Diagnosed PD-L1 CPS Positive Resectable Stage 3-4 Oral Cavity Squamous Cell Carcinoma (OCSCC).

Phase 2 Active not recruiting

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell